

# The solution structure of Dead End bound to AU-rich RNA reveals an unprecedented mode of tandem RRM-RNA recognition required for mRNA repression

## Authors

Malgorzata M. Duszczak<sup>1\*</sup>, Harry Wischnewski<sup>2</sup>, Tamara Kazeeva<sup>1</sup>, Fiona E. Loughlin<sup>1,4</sup>, Christine von Schroetter<sup>1</sup>, Ugo Pradère<sup>3</sup>, Jonathan Hall<sup>3</sup>, Constance Ciaudo<sup>2\*</sup>, Frédéric H.-T. Allain<sup>1,5\*</sup>

## Affiliations

<sup>1</sup>Institute of Molecular Biology and Biophysics and <sup>2</sup>Institute of Molecular Health Sciences, Department of Biology, <sup>3</sup>Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zürich, 8093, Zürich, Switzerland <sup>4</sup>Present Address: Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Clayton, 3800 VIC, Australia <sup>5</sup>Lead Contact

## Contact Information

\*To whom correspondence should be addressed.

E-mail: malgosia@mol.biol.ethz.ch (M.M.D.), cciaudo@ethz.ch (C.C.), allain@mol.biol.ethz.ch (F.H.-T.A.)

## Abstract

Dead End (DND1) is an RNA-binding protein essential for germline development through its role in the clearance of AU-rich mRNAs. Here, we present the solution structure of its tandem RNA Recognition Motifs (RRMs) bound to AU-rich RNA. The structure reveals how an NYAYUNN element is recognized in agreement with recent genome-wide studies. RRM1 acts as a main binding platform, including unusual helical and  $\beta$ -hairpin extensions to the canonical RRM fold. RRM2 acts cooperatively with RRM1, capping the RNA in an unprecedented mode of tandem RRM-RNA recognition. We show that mutation of the RNA-binding interface of the RRM1 weakens affinity and repression of a reporter gene by DND1 depends on its double-stranded RNA binding domain (dsRBD). Our results point to a model where RNA recognition by DND1 is mediated by an uncanonical mode of binding by the tandem RRM1 and a role for the dsRBD in the recruitment of repressing factors.

## Introduction

Post-transcriptional gene regulation (PTGR) is orchestrated by an interplay between mRNA sequence and structure and its dynamic interactions with RNA binding proteins (RBPs). RBPs instantly cover mRNA transcripts as they are transcribed and are essential for all aspects of RNA metabolism like maturation, transport, cellular localization and turnover. Differential gene expression patterns depend on tissue-specific RBP levels and their combined interactions with the transcriptome. Misregulation of this process due to mutations in the RBPs or RNA they bind to is at the origin of a plethora of genetic diseases<sup>1</sup>. Understanding how RBPs specifically recognize their mRNA targets and how this is connected to their downstream fate is therefore crucial to understand the complex PTGR networks involved in health and disease.

The germline is composed of highly specialized cells which must preserve a totipotent genome through generations. It succeeds in this through a highly specialized RNA metabolism regulating a highly complex transcriptome<sup>2,3</sup>. Whereas 8% of all human proteins show highly tissue-specific expression, this is the case for only 2% of RBPs and the majority of these are found in the germline, reflecting its unique specialization<sup>4,5</sup>.

Dead End (DND1) is one of these few germline-specific RBPs. Conserved in vertebrates, it is essential for the specification and migration of primordial germ cells (PGCs), pluripotent germline precursors, to the future reproductive organs. These processes occur early in embryogenesis by blocking the expression of somatic genes, controlled by extensive post-transcriptional regulation<sup>3,6</sup>. DND1 deletion causes loss of PGCs by reactivation of somatic gene expression patterns in zebrafish<sup>7,8</sup>. In mice, truncations of DND1 (the so-called 'Ter-mutation') lead to male sterility and the formation of testicular teratomas<sup>9,10</sup>.

Two mechanisms through which DND1 regulates mRNA transcripts have been proposed. First it was shown that DND1 stabilizes specific tumor suppressors mRNAs in a human tumor cell line (p27/CDKN1B and LATS2), as well as Nanos/TDRD7, essential factors for germline development, in zebrafish embryos, by preventing miRNA-mediated repression of these targets through the binding to conserved U-rich regions (URRs) close to miRNA seed sequences in their mRNA 3' untranslated regions (3'UTRs). This would potentially block their accessibility to the RNA-induced silencing complex (miRISC) which would rescue translation<sup>11</sup>. Second, DND1 was shown to have an opposite effect and a wider role in germ cell PTGR by destabilizing a set of transcripts that must be cleared from developing germ cells to ensure survival, through non-miRISC mediated recruitment of the CCR4-NOT deadenylase complex<sup>12,13</sup>.

Photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) assays revealed that targets crosslinked to DND1 are enriched in a UUU/UUA triplet and are associated with apoptosis, inflammation and signaling pathways<sup>13</sup>. An additional RNA-Immunoprecipitation (RIP)

approach described [A/G/U]AU[C/G/U]A[A/U] as RNA recognition element (RRE) enriched in DND1 targets<sup>9</sup>. Transcriptome sequencing of the Ter mouse line, possessing a truncation in the DND1 gene, just before the formation of teratomas, showed two groups of DND1 targets either up- or down-regulated, involved in pluripotency and in differentiation, suggesting a dual role for DND1. Overall, these functional and genome-wide RRE identification studies using high-throughput methods are partly contradictory and the molecular details on how DND1 achieves target specificity remain elusive.

Most RNA binding proteins exert their specific functions by combining several copies of RNA binding domains to increase specificity and affinity to their targets<sup>14,15</sup>. DND1 has a unique domain structure, carrying two RNA recognition motifs (RRMs) connected by a remarkably short, four-residue inter-domain linker, which are followed by a double-stranded RNA binding domain (dsRBD) (Fig. 1A). This combination of domains is rare among RBPs and is only shared by two other members of the hnRNPR-like subfamily<sup>16</sup> (Figs. S1A, S2). RRMs are the most abundant RNA binding domains in higher vertebrates, binding primarily single stranded RNA<sup>17,18</sup>. Their conserved canonical fold is  $\beta\alpha\beta\beta\alpha\beta$  – a four-stranded anti-parallel  $\beta$ -sheet packed on top of two  $\alpha$ -helices. Their canonical mode of RNA binding involves stacking of two consecutive RNA bases by exposed aromatic residues from the two conserved consensus sequences (RNP1 & RNP2) in the first and third  $\beta$ -strands (Fig. S1B). The RRM has developed several strategies to increase specificity and affinity towards its targets by using extensions to the canonical fold with structural elements outside the  $\beta$ -sheet for RNA recognition and also by employing several copies of the domain. While RRM1 appears to be a canonical RRM, RRM2 on the contrary does not have any aromatic residues in RNP1 and RNP2 (Figs. 1A, S1B, S2). Although several structures of tandem RRM-RNA complexes have been determined<sup>19–24</sup>, the great majority of them contains combinations of two canonical RRMs. It is therefore intriguing to understand if and how the tandem RRMs of DND1 can eventually cooperate to specifically recognize their RNA targets and if the dsRBD further influences RNA binding.

To address the question of how DND1 recognizes and represses its cellular targets at the molecular level, we first set out to understand the contribution of the three RNA binding domains of DND1 to target recognition. This revealed a crucial role for the RRMs while removal of the dsRBD had no effect on target binding. We then determined the solution structure of the DND1 tandem RRMs in complex with an AU-rich RNA. Our structure reveals binding to seven nucleotides with limited sequence-specific interactions generating recognition of a very degenerate NYAYUNN motif. Both RRMs participate in this RNA recognition via an unprecedented mode of cooperative binding by tandem RRMs. A canonical mode of binding by RRM1 is extended by additional secondary structure elements and contacts to RRM2 originating from  $\alpha$ -helix 2 which is unique amongst known RRM-RNA interactions. Our structure explains the degeneracies in the RREs found in recent CLIP and RIP studies. Finally, we show, using luciferase-based assays, that an AU-rich RRE is necessary and sufficient for translational repression by DND1 and that mutations in the RNA binding surface of DND1's tandem RRMs rescue target translation. Surprisingly, also removal of the dsRBD recovers

translation in full, suggesting that the dsRBD is an essential effector domain likely to recruit destabilizing factors like CCR4-NOT. These results provide the first mechanistic and structural insights into the molecular mechanisms by which DND1 represses a subset of mRNAs and in turn stabilizes the fate of germ cells.

## Results

### DND1 binds CLIP/RIP targets *in cellulo* mainly through its RRM1

There is some ambiguity in the published RRE targeted by DND1. It was first reported, using reporter assays, that DND1 binds to U-rich regions (URRs) of approximately 12 nucleotides in length in the vicinity of miRNA seed sequences in the 3'UTR of the CDKN1B/p27 tumor suppressor mRNA, with the sequences UUUUCCUUAUUU and UUUUUACCUUUU<sup>11</sup>. Much later, genome-wide PAR-CLIP studies defined as RRE a much shorter UUU/UUA triplet<sup>13</sup> and very recently a RIP approach revealed [A/G/U]AU[C/G/U]A[A/U] as RRE enriched in DND1 targets<sup>9</sup>. A single RRM usually binds 4-6 nucleotides<sup>17</sup>. To understand how a protein with two RRMs and a dsRBD recognizes an RNA target, we set out to define the contributions of each domain to RNA binding. We first selected published DND1 targets and validated them using RIP (RNA immunoprecipitation) from HEK293T transiently expressing either wild-type (WT) or mutant FLAG-tagged DND1. Mutant 1-235 lacks the dsRBD but includes the extended RRM2, making it longer than the Ter-mutation truncation<sup>10</sup>, which is located in the middle of RRM2  $\alpha$ -helix 2 (Fig. 1A). R98A is a mutant of the conserved RNP1 sequence in RRM1 (Figs. 1A, S1B). The RIP was followed by quantitative PCR using primers for two DND1 targets revealed by PAR-CLIP and RIP (Fig. 1B). Phorbol-12-Myristate-13-Acetate-Induced Protein 1 (PMAIP1), a cell cycle regulator promoting apoptosis, is the target with the highest normalized 3'UTR read counts in the PAR-CLIP dataset<sup>13</sup>. Survival of Motor Neuron (SMN) protein is a small nuclear ribonucleoprotein (snRNP) assembly factor. Its pre-mRNA SMN1 is expressed at an order of magnitude lower level than PMAIP1 in HEK293 and is enriched in the RIP dataset<sup>9</sup>. As a negative control, we used solute carrier family 25 member 6 (SLC25A6), with HEK293 mRNA levels in the same order of magnitude as PMAIP1. In our RIP assays using both the full-length WT DND1 and a truncation mutant lacking the dsRBD, the enrichment over the input is increased for the two targets compared to the control (Figs. 1B, S3B). Pulldown by the full-length R98A mutant results in a level of target enrichment comparable to the negative control pulled down by the WT DND1. These data suggest that RRM1 might be utilized as an essential RNA binding interface in cells, while the dsRBD appears not to be involved in RNA binding, at least for these two abundant targets. The role of RRM2 could not be tested considering the non-canonical nature of this RRM as its RNA interaction surface could not be predicted. Therefore, we next decided to investigate the contribution of the individual RRMs to RNA binding *in vitro*.

## DND1's tandem RRM's cooperatively bind AU-rich RNA with high affinity

To define high affinity RNA targets for the individual RRM's, we recombinantly expressed and purified the separate RRM domains, including the conserved N- and C-terminal extensions (Figs. 1A, S2). We then tested their binding to short oligonucleotides derived from the p27 URRs<sup>11</sup> using Isothermal titration calorimetry (ITC) to monitor thermodynamic changes upon ligand binding (Fig. 2). In addition, we used NMR titrations, series of two-dimensional <sup>1</sup>H-<sup>15</sup>N HSQC spectra of protein with increasing RNA concentrations, to observe backbone amide proton chemical shift perturbations caused by RNA binding (Fig. 2B and S4ABC). We found that RRM2 alone does not bind any of the oligos (Fig. S4A) and that only an oligo including a central adenosine (UUAUUU) has enough affinity to RRM1 to show significant chemical shift perturbations in an NMR titration (Fig. S4B). The affinity of this UUAUUU oligo to RRM1 is 34.4 μM as measured by ITC (Fig. 2A). Surprisingly, the affinity to this sequence increased over 7-fold (4.7 μM K<sub>D</sub>) when titrated to the tandem RRM domains showing a role for RRM2 in RNA binding. NMR titration of this oligo to DND1 RRM12 indicates a change from fast to intermediate exchange regime on the chemical shift timescale and saturation of most residues at a 1:1 ratio, which is consistent with the increased affinity measured by ITC (Fig. 2B). Large chemical shift changes throughout the <sup>1</sup>H-<sup>15</sup>N HSQC spectrum indicate major structural rearrangements of the tandem RRM's upon RNA binding. Additional NMR titrations showed that only the tandem RRM's, not the single domains, have some affinity to U-rich oligos not containing adenosines or with an adenosine at the periphery such as UUUUCC and UUUUUAC (Fig. S4C). To test if the tandem RRM's could bind a longer oligo with even higher affinity, we extended the oligo UUAUUU at the 5' end which resulted in a modest increase in affinity to the tandem RRM's (1.2 μM K<sub>D</sub> for UCCUUAUUU, Fig. S4D) and an extended oligo with cytidines following the central adenine (UUUUUACCU) resulted in a decrease in affinity to 8.2 μM (Fig. S4E). The *in vitro* binding measurements are summarised in Table S2. Taken together the results above indicate that the DND1 tandem RRM's cooperatively bind AU-rich RNA targets of approximately 5 nucleotides in length, with the highest affinity when the adenine is in a central position.

## The solution structure of DND1's tandem RRM's bound to CUUAUUUG RNA

To understand the mechanism of cooperative binding of DND1's tandem RRM's and their preference to AU-rich over U-rich RNAs, we solved the structure of the extended RRM12 in complex with an RNA target using NMR spectroscopy (Table 1, Fig. 3). We chose the 8-mer oligo CUUAUUUG for our structure determination as we expected capping the high-affinity UUAUUU oligo with other types of nucleotides to facilitate resonance assignment. The assignment procedure of protein and RNA and the structure calculation protocol is outlined in the STAR Methods details. DND1 RRM12 showed poor solubility and in the final stages of purification was purified in complex with the target RNA. Use of selectively ribose <sup>13</sup>C-labeled CUUAUUUG RNA prepared by solid phase synthesis from phosphoramidites helped resolving spectral overlap of critical residues, greatly aiding assignments of resonances and intermolecular NOEs (Fig. S5A). We could calculate a precise structural ensemble of this 27.5 kDa protein-RNA complex using unambiguous intra-protein (4947), intra-

RNA (150) and intermolecular (103, Table S3) NOE-derived distance restraints. The isolated domains within this ensemble of 20 conformers converge to a root mean square deviation (RMSD) of 0.95 Å (RRM1), 0.57 Å (RRM2) and the U<sub>3</sub>A<sub>4</sub>U<sub>5</sub>U<sub>6</sub>U<sub>7</sub> RNA nucleotides to an RMSD of 0.6 Å for all heavy atoms (Figs. 3AB, Table 1). The global complex was initially less well defined due to a lack of direct contacts between RRM1 and RRM2 and a limited number of restraints that could orient the domains through the RNA. We did expect a well-defined orientation between RRM1 and RRM2 in the complex though, as <sup>15</sup>N T1 and T2 relaxation measurements indicated the protein-RNA complex behaves as a rigid globular protein of approximately 30 kDa in solution as opposed to two domains tumbling independently (Fig. S5B). We included 127 Residual Dipolar Couplings (RDCs) from amide bonds to increase precision and obtained a precise final ensemble of 20 conformers with an RMSD of 1.26 Å for all heavy atoms (Fig. 3C, Table 1).

Our structure reveals a number of unusual structural features including unprecedented modes of RRM:RNA recognition. The fold of RRM1 is non-canonical with the conserved N-terminal extension folding into a  $\beta$ -hairpin packed on top of an N-terminal  $\alpha$ -helix. This structural element is tightly packed against the side of the RRM1 to create an extended surface (Fig. 3A), in an identical fashion as the extension of RRM1 in the RNA-binding protein hnRNPQ/SYNCRIP<sup>25</sup>. This extended RRM (eRRM) fold is conserved in all members of the hnRNPR-like family of RNA binding proteins (Figs. S1, S6). RRM2 is followed by the conserved C-terminal helical extension lacking contacts to the core canonical RRM2 fold (Fig. 3B), as confirmed by the relaxation data which shows this helix tumbling independently in the tandem RRM-RNA complex (Fig. S5B). The RNA is bound in a canonical 5' to 3' fashion over  $\beta$ 4 through to  $\beta$ 2 using the RNP residues of RRM1 but is sandwiched between the two domains (Fig. 3D), burying the central UAUUU nucleotides in a positively charged channel (Fig. 3E). In addition to the primary RNA binding surface on RRM1, the conserved N-terminal hairpin extension is used to extend RNA binding for a longer sequence compared to canonical RRMs. Finally, and most surprisingly, this RNA binding is stabilized by RRM2 using an unprecedented binding pocket formed by RRM2  $\alpha$ -helix 2 and the edge of its  $\beta$ 4, while the non-canonical  $\beta$ -sheet of RRM2, missing conserved aromatic RNP residues, is turned away from the RNA. Additional protein-RNA contacts are facilitated by the backbone and sidechains of the four-residue interdomain linker. This structure explains well the increase in RNA binding affinity of the tandem RRMs compared to RRM1 in isolation.

### **Structural details: specific readout by DND1's tandem RRMs**

DND1's tandem RRMs directly bind primarily the central 5 nucleotides (**bold**) of CU**UAUUUG** RNA (Fig. 4). The intermolecular contacts are represented in a schematic fashion in Figure 4A. U<sub>3</sub> and A<sub>4</sub> are bound in a canonical fashion over the RRM1  $\beta$ -sheet surface, their bases interacting with  $\beta$ 4 and  $\beta$ 1 respectively. The U<sub>3</sub> O2 is hydrogen-bonded to the C132 sidechain and its sugar ring contacts L130. The A<sub>4</sub> base is stacked on F61 in RNP2 and its sugar ring interacts with F100 from RNP1 in a canonical manner (Fig. 4B). This is illustrated by unusual chemical shifts of the A<sub>4</sub> ribose carbons and protons (Fig. S5A). The A<sub>4</sub> base is sequence-specifically recognized via

hydrogen-bonds to its Hoogsteen edge (N4 amino and N7) from side-chains and main-chains of the highly conserved interdomain linker (R133, S134 and T135) (Figs. 4B, C). We see variability in the H-bond partners to A<sub>4</sub> in the structural ensemble, which reflects the exchange-broadening we observe for the backbone resonances of these linker residues.

From U<sub>5</sub> onwards the protein-RNA interactions deviate from canonical binding. While in a canonical RRM the U<sub>5</sub> base would be expected to stack on the RNP2 Y102, here U<sub>5</sub> rather stacks on top of the A<sub>4</sub>, as evidenced by strong NOEs between A<sub>4</sub> H1' to the U<sub>5</sub> H5 and H6 resonances and weaker NOEs between A<sub>4</sub> H8 to the U<sub>5</sub> H6 resonance (Table S3). The sugar ring of U<sub>5</sub> is packed against Y102, F100 and M90 (Fig. 4C) and its base functional groups are involved in hydrogen-bonding with the conserved interdomain linker backbone and sidechains (e.g. the S134 hydroxyl, T135 backbone amide and K137 NH<sub>3</sub>, Figs. 4B, D) and with the Y102 hydroxyl.

The most surprising element of the structure is the involvement of a highly conserved binding pocket of RRM2 in the specific recognition of U<sub>6</sub>. U<sub>6</sub> lies under RRM2  $\alpha$ -helix 2 with its ribose ring in contact with A193, M194 and K197 and its base carbonyl O4 hydrogen-bonded by both the NH<sub>3</sub> of K196 and the sidechain HE1 of W215 (Fig. 4D). Contacts to the U<sub>6</sub> and U<sub>7</sub> phosphate groups by H189 and K197 side-chains, respectively, further stabilize the U<sub>6</sub>-RRM2 interaction, defined by a large number of intermolecular NOEs (Fig. S5A). These interactions with RRM2  $\alpha$ -helix 2, grabbing the U<sub>6</sub> nucleotide like a claw, allow for an unusual reversal of the RNA backbone direction at U<sub>6</sub> which is rotated by 120 degrees (around a vertical axis in Fig. 4D) compared to U<sub>5</sub>. The contacts to the U<sub>6</sub> phosphate group by R88 and Q39 of RRM1 (Fig. 4E) help positioning the two RRMs relative to each other and explain their cooperative binding since both RRMs contribute to U<sub>6</sub> binding.

The U<sub>7</sub> phosphate is fixed by a salt bridge to K197 on RRM2 while the sidechain NH<sub>2</sub> of N37 on the tip of the N-terminal eRRM hairpin extension interacts with the G<sub>8</sub> phosphate (Fig. 4D). The U<sub>7</sub> base is not sequence-specifically recognized. Finally, the G<sub>8</sub> nucleotide is not well defined. Overall, in this conformation all phosphate groups from U<sub>3</sub> to G<sub>8</sub> are hydrogen-bonded to one or two protein side-chains with some originating from the RRM1 extension (N37 on  $\beta$ -strand -1 and Q39 on  $\beta$ -strand 0). Altogether this structure suggests the recognition of a N<sub>2</sub>Y<sub>3</sub>A<sub>4</sub>Y<sub>5</sub>U<sub>6</sub>N<sub>7</sub>N<sub>8</sub> consensus sequence (where Y is a pyrimidine) by DND1s tandem RRMs as in the positions of U<sub>3</sub> and U<sub>5</sub> cytosines could be accepted while keeping the H-bond network at least partly intact.

The binding topology on the eRRM1 and RRM2 is unprecedented with for the first time the involvement of a nucleotide binding pocket in  $\alpha$ -helix 2 of an RRM. As the  $\beta$ -hairpin extension and RNA binding residues on eRRM1 are conserved in the hnRNPR-like family of RNA binding proteins (Figs. S1, S6) it is likely that the RNA binding mode of the eRRM1 is conserved. Although the interdomain linker, comprised of amino acid residues TEK, is unique for DND1 within this family, it is possible that the linkers of the other family members could bind RNA in a similar fashion but

using an alternative H-bonding network. Notably, DND1 is the only family member with a non-canonical  $\beta$ -sheet binding surface for RRM2, lacking aromatic residues.

### **Mutation of key RNA binding residues compromises the RNA interaction *in vitro*.**

To further understand the structure, we replaced several RNA interacting residues of DND1's tandem RRMs with alanine and tested the effect of these substitutions on RNA binding by NMR titrations, after making sure that the protein fold was not affected (Fig. S7A). The mutant of a canonical RRM1 RNP residue R98A failed to bind CUUAUUUG (Fig. S7B), confirming *in vitro* that the eRRM1 is the primary RNA binding surface of DND1 as shown by our RNA-IP and qPCR experiments (Figs. 1B, S3). Of note, other RRM1 RNP mutants could not be tested. Although we could express mutant F61A, it precipitated during the purification, while Y102A could not be expressed in the soluble fraction at all, despite the fact that its equivalents were used in several studies as RNA binding mutants<sup>11,26–28</sup>. Although its solubility *in cellulo* and *in vivo* might be improved, its inactivity could result from an overall instability of the protein. Mutation of M90 on  $\beta$ 2 of eRRM1, a residue interacting with U<sub>5</sub>, also abolishes RNA binding (Fig. S7B). Although the linker T135 sidechain makes several specific contacts with A<sub>4</sub> or U<sub>5</sub>, mutation of this residue to A does not reduce RNA binding. Most likely other residues in the linker could compensate using an alternative H-bonding network for binding to U<sub>5</sub>. K197A and W215F mutations of residues of the unusual RNA binding pocket of RRM2, result in weaker binding. Smaller chemical shift changes are seen in W215F compared to the WT upon RNA titration. In the K197A mutant, the NMR signals of the complete RRM2  $\alpha$ -helix 2 are exchange-broadened in the RNA-bound state, indicating a less stable RNA binding. These assays confirm that eRRM1 RNP is essential for RNA binding and that the novel RRM2 binding pocket stabilizes the primary eRRM1-RNA interaction.

### **Introduction of an AU-rich RRE into a reporter gene 3'UTR is necessary and sufficient for target repression by DND1**

To investigate how the reduced RNA binding caused by these mutations affects DND1's function *in cellulo*, we set out to test these single amino-acid mutants in the context of the full-length protein, in a luciferase-based gene reporter assay. Kedde et al. used such assay earlier to show that DND1 protects certain mRNA targets from miRNA-mediated repression<sup>11</sup>. As reporter, we transfected the psiCHECK2 dual luciferase plasmid with a partial p27/CDKN1B 3'UTR sequence into HEK293T cells. The partial UTR, cloned downstream from the Renilla luciferase ORF, contains two miR-221 seed sequences and two putative DND1 binding sites, identical to the sequence shown by Kedde et al.<sup>11</sup> to be sufficient for protection of the target by DND1. Upon co-transfection of a miR-221-3p mimic (miRIDIAN, Dharmacon), we unexpectedly observed an increase of the luciferase activity compared to the co-transfection of a negative control scrambled miRNA mimic, contradicting the expected repression (Fig. S8), a hitherto undescribed off-target effect of this system. Introduction of a plasmid expressing FLAG-tagged wild-type DND1 had a repressive effect on p27-3'UTR targets independent



of which miR-mimic was transfected – either the miR221-mimic targeting the UTR or the negative control – while the DND1-mediated target repression was only significant in the presence of the negative control miR mimic. We conclude that DND1 has a repressive effect on the p27/CDKN1B 3'UTR target independent of targeting by a miRNA in this system, but due to the significant off-target effects of the miR-221 mimic, we cannot reliably use this system to investigate the role of RNA binding in DND1-mediated repression.

To more reliably investigate the DND1-mediated target repression observed, we inserted the full 3'UTR from the telomerase reversed transcriptase gene (TERT) into the psiCHECK2 dual luciferase plasmid. It is not expected to be targeted by DND1 as it lacks AU-rich regions and was not found among the recent CLIP and RNA-IP DND1 target datasets<sup>9,13</sup>. Upon transfection of this reporter into HEK293T cells together with expression plasmids for either wild-type or mutant full-length FLAG-tagged DND1, we do not observe any effect on luciferase activity (Fig. 5). Yet, insertion of a single UAUUU (the central pentanucleotide bound to the tandem RRM in our structure) into the TERT 3'UTR is sufficient to reduce luciferase upon transfection of wild-type DND1. This reduction is significant if two consecutive UAUUU sequences (spaced by a UUUU tetranucleotide) are introduced. Transfection of the R98A eRRM1 RNP mutant or the truncation mutant lacking the dsRBD (DND1 1-235) rescues the luciferase activity. These results indicate that the presence of an AU-rich RRE in the 3'UTR is necessary and sufficient for DND1-mediated target repression. While the dsRBD-truncation mutant is unable to repress targets here, our RNA-IP followed by q-RT-PCR (Figs. 1B, S3) show that it is not deficient in RNA binding, so RNP-mediated RRE recognition by DND1's tandem RRMs is necessary, but not sufficient for target repression. This suggests that the dsRBD might have a downstream role in DND1-mediated gene repression that is apparently independent of RNA binding.

## Discussion

### **Unique arrangement of DND1's tandem RRM's dictates conformation, orientation and accessibility of bound RNA**

We determined the solution structure of DND1's extended tandem RRM's in complex with AU-rich RNA and show the molecular details of target RNA recognition by this RNA binding protein that is essential for germ cell survival in higher vertebrates. Previously solved tandem RRM-RNA complexes have shown either formation of a cleft, like Sex-Lethal (Sxl)<sup>29</sup> and Human Antigen D (HuD – Fig. 6A)<sup>24</sup>, or extended surfaces (Poly-A Binding Protein (PABP – Fig. 6B)<sup>20</sup> and TAR DNA-binding protein 43 (TDP-43 – Fig. 6C)<sup>22</sup> by the two canonical  $\beta$ -sheet surfaces accommodating the RNA. In all these structures RNA stretches between 8–10 nucleotides are bound in a canonical fashion, with higher affinity and specificity than if a single domain is used. In all the tandem RRM's mentioned above, the bound RNA adopts an extended conformation. The RRM-RRM orientation and RNA binding topology are completely different in our DND1-RNA structure, which is a result of four structural features found so far only in this complex: lack of a canonical RNA binding surface for RRM2, an ultra-short inter-RRM linker, an extended RNA binding surface of eRRM1 and finally, the presence of an unprecedented RNA binding pocket on  $\alpha$ -helix 2 of RRM2. The complex embeds only a short canonical RNA binding stretch (U<sub>3</sub>-A<sub>4</sub>), which is followed by binding of U<sub>5</sub>-U<sub>7</sub> in a very unusual manner. Indeed, U<sub>6</sub> is bound by RRM2  $\alpha$ -helix2, resulting in a 120-degree rotation of U<sub>6</sub> compared to A<sub>4</sub> and the U<sub>7</sub> ribose is bound by the tip of the eRRM1 extension. Binding by the linker residues supports the RNA in this unique conformation, its short length being likely crucial to bridge nucleotides specifically recognized by RRM2 and eRRM1. The path of the RNA backbone is reversed, and the RNA is more compacted than in previously determined tandem RRM-RNA complexes, the U<sub>3</sub>-G<sub>8</sub> phosphates spanning approximately 21-23 Å (Fig. 6D), while e.g. in PABP an equivalent stretch of 6 nucleotides spans approximately 26-28 Å (Fig. 6B). Such backbone reversal capacity might help to fold the RNA, or the tandem RRM's might be suited to recognize an RNA that is in an extended stem-loop conformation. Also, the central RNA residues are not solvent accessible compared to other tandem RRM-RNA complexes. This structural feature would be consistent with the possibility that DND1 acts as a steric inhibitor of effector complexes targeting proximal binding sites like suggested for the miRNA seed sequences targeted by miRISC in p27/CDKN1B and LATS2<sup>11</sup>.

### **Structural extension of the eRRM1 increases RNA binding affinity and stabilizes a backbone turn in the recognized RNA.**

While several extensions to the canonical RRM fold have been described, either extending the  $\beta$ -sheet surface by one or several strands or adding an  $\alpha$ -helix at the N-or C-terminus<sup>14</sup>, the DND1 N-terminal extension of a  $\beta$ -hairpin packed on a third  $\alpha$ -helix is so far restricted to the hnRNPR-like family of proteins (Figs. S1, S6). An X-ray structure of such eRRM from another member of this family,

SYNCRIP/hnRNPQ in its free form has been published recently<sup>25</sup> and is highly similar to the DND1 eRRM1 with the exception of the formation of the  $\beta 3'/3''$  hairpin and a small shift in the orientation of the N-terminal extension. These differences are likely due to RNA binding in our structure or the presence of an additional N-terminal acidic domain (AcD) found in the SYNCRIP structure. Our structure reveals that this  $\beta$ -hairpin packed on a third  $\alpha$ -helix is essential for increasing the affinity to the RNA by fixing the backbone of U<sub>7</sub> and G<sub>8</sub> on the eRRM1 via N37 and Q39 (Figs. 4D, E). Therefore, it is crucial for stabilizing the turn in the backbone observed in our complex. This is reminiscent of other extensions found in the RRM contributing to RNA binding like the  $\beta$ -hairpin found in FUS RRM<sup>30</sup> (Fig. 6E) and the fifth  $\beta$ -strand of PTB RRM2<sup>31</sup> (Fig. 6F).

### **The hrRRM2 presents a novel RNA binding pocket and its integrity is necessary for DND1 function.**

We have shown that the primary RNA interaction interface of DND1 lies on eRRM1. It is the proximity of the second RRM, lacking a canonical RNA binding interface, but presenting a novel pocket for stabilization of this primary binding, that makes the RNA binding topology by DND1's tandem RRMs unprecedented. Structures of several types of RRM domains without aromatic residues on the  $\beta$ -sheet surface have been described<sup>14</sup>. The qRRMs of hnRNPF use their  $\beta 1/\alpha 1$ ,  $\beta 2/\beta 3$ , and  $\alpha 2/\beta 4$  loops for recognition of G-rich sequences<sup>32</sup>, while the  $\Psi$ RRM of SRSF1 uses a conserved motif in the  $\alpha$ -helix1 for purine-rich RNA binding<sup>33</sup>. However, our structure is the first example of an RRM mediating RNA binding via  $\alpha$ -helix2. We propose to call an RRM using this interface for RNA binding the hrRRM for hnRNPR-like family related RRM. We demonstrated the importance of the binding pocket on RRM2 by mutational analysis using *in vitro* binding assays (Fig. S7B). It is also supported by its almost full conservation, not only in DND1 (Fig. S2) but also other members of the hnRNPR-family (Fig. S6). Thus, its RNA binding mode is likely to be conserved. Our RRM2 structure is highly similar to the structure of the free RRM2 of RBM46 (RNA binding motif protein 46, PDB: 2DIS)<sup>34</sup> including the orientation of the residues of the novel binding pocket. The importance of this pocket for DND1 function was demonstrated in functional studies in zebrafish where the equivalent to the K197 mutant (K200T) was the only mutant outside of RRM1 causing loss of function<sup>28</sup>. Nearly all other loss-of-function mutants in this study can be explained using our structure. We already discussed the zebrafish Y104 RNP mutant: the equivalent of Y102 in humans, is unstable *in vitro*. Even if it would be stable *in vivo*, interactions with U<sub>5</sub> would be lost. The equivalents of Y72, F89 and H121 in zebrafish *dnd1* are Y70, F87 and H119 in human DND1. They are important structural residues stabilizing the RRM fold. Y70 is particularly important for interaction between  $\alpha$ -helices 0 and 1 in eRRM1, linking the core RRM fold and the N-terminal eRRM extension. Mutation of these residues most likely disrupts the fold of eRRM1. The only loss-of-function mutant that is not that easily explained is N94K, a mutant of the equivalent T92 in the human protein, situated in the  $\beta 2$ - $\beta 3$  loop. This residue is in close proximity to G<sub>8</sub> in our structure, but not well enough defined to interpret a specific interaction with the RNA. In the context of a longer RNA it could very well be involved in such

specific binding. Finally, it should be mentioned that the Ter mutation, causing germ cell loss and testicular teratomas in mice<sup>10</sup>, is a truncation at the equivalent of R190 in  $\alpha$ -helix 2, demonstrating that RRM2 and the dsRBD are essential domains for DND1 function. The novel binding pocket in RRM2 increases affinity and specificity to the readout of eRRM1 and creates a remarkable turn in the RNA backbone.

## Limited sequence specificity leads to plasticity of RNA recognition

The RNA recognition observed in our structure unifies seemingly contradictory data present in the literature as to the RNA recognition elements found enriched in DND1 targets. In fact, a combination of a UUA/UUU triplet as enriched in CLIP<sup>13</sup> was used in our structure determination as the RNA target. The motif Y<sub>3</sub>A<sub>4</sub>Y<sub>5</sub>U<sub>6</sub>N<sub>7</sub>N<sub>8</sub> derived from our structure also fits with the [A/G/U]AU[C/G/U]A[A/U] motif enriched in RIP targets<sup>9</sup>. Moreover, this motif may be interpreted as a repetition of the UAU motif, containing 2 adenines that are specifically recognized in our structure. We have not tested binding to an oligonucleotide containing two spaced adenines, but the avidity effect of RBPs binding to repetitions of high affinity motifs, increasing affinity, has been demonstrated for several other RRM-containing proteins: hnRNPG<sup>35</sup>, PTB<sup>31</sup>, hnRNP C<sup>36</sup> and more recently HuR<sup>37</sup>. Our structure also provides some insight how the residues outside of the YAY motif could be recognized. For example, the binding pocket on RRM2 specifically recognizing U<sub>6</sub> in our structure (Fig. 4D) could not accommodate a C without losing the double H-bond to the O4. Indeed, when comparing the binding of UUUUUACCU and UCCUUAUUU using ITC (Fig. S4), we observe an eight-fold reduced affinity. Overall, it looks like DND1's tandem RRMs demonstrate a certain plasticity for RNA recognition where a range of sequences can be bound, but a Y<sub>3</sub>A<sub>4</sub>Y<sub>5</sub>U<sub>6</sub> is necessary for high affinity binding. Such high affinity binding could be a prerequisite for the activation of downstream processes like the recruitment of repressing factors like the CCR4-NOT complex<sup>38</sup>. Here, we propose that the tandem RRMs bind RNA in a two-step mechanism. In a first step a range of sequences may be preselected by low affinity binding in order to attach DND1 to scan the 3'UTR (Fig. 6G panel a). Upon encountering a high-affinity YAYU element the DND1 pauses at the central adenine (A<sub>4</sub>), while RRM2 locks the uridine (U<sub>6</sub>) in its hrRRM binding pocket which can then initiate downstream processes from a fixed position (Fig. 6G panel b).

## Role of the dsRBD

We have shown that DND1's tandem RRMs, like the majority of RRMs, are relatively sequence tolerant<sup>14</sup>. On the other hand, we know that linear sequence motifs are often insufficient to fully capture RBP binding specificities<sup>39</sup>. Specificity may be increased due to contextual features, either in the form of bipartite motifs, such as recently found for FUS<sup>30</sup>, preference for a nucleotide composition flanking a high affinity linear motif, or due to the favoring of specific structural motifs adjacent to the linear motif. The fact is that while the RNA binding surfaces of the tandem RRMs are highly conserved within the hnRNPR-like family of proteins, the sequences of the dsRBDs of DND1, RBM46 and ACF1

(APOBEC1 complementation factor) are not that well conserved (Fig. S6B). Thus, DND1's highly specialized function in germline development might originate from this domain. We have shown that DND1's dsRBD is required for target repression, presumably through direct or indirect recruitment of effector proteins like the CCR4-NOT complex, but also that DND1's dsRBD is not essential for RNA binding (Figs. 1B, S3). Although DND1's dsRBD lacks some canonical RNA recognition residues<sup>40</sup> (Fig. S6B), we cannot exclude a non-canonical RNA binding surface to contribute to the binding to a set of targets. The dsRBD could increase DND1's target specificity by recognizing a stem-loop motif adjacent to the linear motif recognized by the tandem RRM. While we know that 3'UTRs are highly structured not only *in vitro* but also *in vivo*<sup>41</sup>, it is to be investigated if the 3'UTRs in the vicinity of the linear motifs targeted by DND1 are indeed enriched in secondary structure. Further structural studies should be undertaken to confirm that such structures can indeed be recognized by the full length DND1. Another possibility for increasing target specificity by DND1 is cooperation with a binding partner, as has been reported for NANOS2<sup>42</sup>, which has also been shown to interact with CCR4-NOT<sup>12,43</sup>, or other germline-specific RNA binding proteins.

## **DND1 as a germline-specific AU-rich element binding protein**

DND1 binds UAUU which is contained in AU-rich sequence elements (AREs) in 3'UTRs that have been known for many years to target mRNAs for rapid degradation in mammals. AREs are divided into three classes with respect to the copy number of the canonical pentamer AUUUA sequence: several copies are dispersed between U-rich regions in class I, clustered in class II, while class III are predominantly U-rich but lacking these canonical pentamers<sup>44</sup>. More than 20 AU-rich RNA binding proteins (AUBPs) have been identified, they control the fate of ARE-mRNAs<sup>45</sup>. Because DND1 CLIP and RIP-enriched targets do not necessarily contain the canonical ARE AUUUA pentamer target sequence, DND1 can be classified as a germline-specific AU-rich RBP (AUBP) targeting class III AREs. The recruitment of degradation machineries to mRNAs for their destruction is a unifying mechanism between several AUBPs<sup>46-48</sup>, which is likely shared by DND1. As multiple AUBPs may modulate the stability and translation of a single ARE-mRNA, questions of functional redundancy and additivity or antagonism arise. It is likely that variations in the relative amounts of mRNAs, the AUBPs present in a certain cell type or developmental stage and in the binding affinities, determine both the identity of the targeted mRNAs and their fate<sup>38</sup>. Therefore, the sole fact that DND1 is specifically expressed in the germline will be a major contributing factor to its target specificity. This obviously questions the relevance of recognition motif derivation in large-scale DND1-RNA interaction studies performed in non-native cell types with transcriptomes differing from developing germ cells and using cross-linking that might overrepresent low affinity motifs. The structural and biophysical work in this study contributes to the understanding of what the requirements are for a high affinity motif for DND1 and helps to reinterpret previous studies in order to understand the complex gene regulation networks during germline specification.

We have demonstrated that DND1 prefers AU-rich over U-rich RNAs and that a central adenine is required for high-affinity binding. The adenine is specifically recognized by the eRRM1 binding pocket involving RNP2 and the interdomain linker (position 'N<sub>1</sub>'). This contrasts with the RRM3 of another AUBP, HuR, that recognizes both AU-rich and U-rich sequences with similar affinities, the latter slightly higher due to an avidity effect<sup>37</sup>. Adenines are bound by HuR RRM3 in two different positions: either on the periphery, or  $\beta$ -strand 3 using RNP1 (position 'N<sub>2</sub>'). Adenines are important to localize the protein at a precise position within the 3'UTR. Such a 'locking' mechanism is also present for the cytoplasmic polyadenylation element (CPE)-binding (CPEB) family of RNA-binding proteins. These RBPs bind the CPE sequence UUUUAU, which activates translation by cytoplasmic polyadenylation. The CPEB4 and CPEB1 tandem RRMs bind a UUUUA pentanucleotide sequence-specifically<sup>19</sup>. While the uridines are bound by RRM1, the adenine is specifically recognized by RRM2 using RNP2 (position 'N<sub>1</sub>'). RRM1 in isolation has low affinity to U-rich RNAs and RRM2 does not bind U-rich sequences. Therefore, it is proposed that the protein is recruited to U-rich motifs through RRM1, after which it scans the 3'UTR in an open conformation until it encounters an adenine in a consensus CPE and locks the protein on this sequence. This is a similar mechanism as we propose here for DND1, although in our case the scanning for a high-affinity motif likely happens in a closed rather than open conformation as the isolated RRM1 does not bind U-rich sequences. This original mode of RNA target selection therefore appears to be a general mechanism for cytoplasmic RNA binding proteins regulating RNA via their 3' UTR.

In conclusion, we provide here the first structural and mechanistic insight into the molecular mechanisms by which the RNA binding protein DND1 represses a subset of mRNAs and in turn might stabilize the fate of germ cells. Our results hint at a specialized function of DND1's individual RNA binding domains where the tandem RRMs are mainly responsible for target binding and the dsRBD for target repression, likely through the recruitment of repressing factors. Our structure unifies DND1 RNA recognition elements recently found enriched in genome-wide interaction studies and facilitates understanding of loss-of-function mutants previously described in the literature. In addition, we have demonstrated yet another way in which an RNA recognition motif can recognize RNA, extending the repertoire of this versatile and abundant RNA binding domain.

## Acknowledgments

We are grateful to Gunter Stier (BZH, Universität Heidelberg) and Dr. Arie Geerlof (PEPF Helmholtz Zentrum München) for providing us with expression plasmids and protocols that were developed at EMBL Heidelberg. We thank Dr. Julien Boudet for assistance with ITC measurements, Dr. Antoine Clery for cloning the RRM2 expression plasmid and assistance with ITC, Dr. Fred Damberger for assistance with NMR experiments and structure calculations, Dr. Markus Blatter and Dr. Yaroslav Nikolaev with structure calculation and IT support respectively, Mauro Zimmermann for assistance

with RNA preparation and Dr. Daniel Cirera-Salinas for cloning the psiCHECK-2-TERT plasmid and assistance with luciferase assays. We thank Dr. Nina Ripin and Dr. Fred Damberger for critical reading of the manuscript. NMR was carried out at the Biomolecular NMR Spectroscopy Platform BNSP of the ETH Zurich. This work was supported by the Promedica Foundation (to M.M.D.) and the Swiss National Science Fund SNF (120% Support Grant to M.M.D., NCCR RNA biology & disease and SNF grants 31003A\_149921 and 31003A\_170130 to F.H.-T.A., 31003A\_173120 to C.C.).

## Author Contributions

M.M.D., F.H.-T.A. and C.C. designed the experiments and wrote the paper. M.M.D. prepared samples, solved the structure and ran ITC experiments. H.W. performed luciferase, RIP and qPCR assays. T.K. prepared mutants and samples. F.E.L. designed and performed the RRM2 titration experiments. C.v.S. prepared mutants. U.P. synthesized selectively labeled RNA oligos. M.M.D., F.H.-T.A. H.W. and C.C. analyzed data. F.H.-T.A., J.H. and C.C. provided funding and resources.

## References

1. Corbett, A. H. Post-transcriptional regulation of gene expression and human disease. *Curr. Opin. Cell Biol.* **52**, 96–104 (2018).
2. Ramsköld, D., Wang, E. T., Burge, C. B. & Sandberg, R. An Abundance of Ubiquitously Expressed Genes Revealed by Tissue Transcriptome Sequence Data. *PLoS Comput. Biol.* **5**, e1000598 (2009).
3. Seydoux, G. & Braun, R. E. Pathway to Totipotency: Lessons from Germ Cells. *Cell* **127**, 891–904 (2006).
4. Dezsó, Z. *et al.* A comprehensive functional analysis of tissue specificity of human gene expression. *BMC Biol.* **6**, 49 (2008).
5. Gerstberger, S., Hafner, M., Ascano, M. & Tuschl, T. in *Systems Biology of RNA Binding Proteins. Advances in Experimental Medicine and Biology*, vol 825. (ed. Yeo, G.) 1–55 (Springer, New York, NY, 2014).
6. Licatalosi, D. D. in *Advances in Experimental Medicine and Biology* **907**, 123–151 (Springer, Cham, 2016)
7. Gross-Thebing, T. *et al.* The Vertebrate Protein Dead End Maintains Primordial Germ Cell Fate by Inhibiting Somatic Differentiation. *Dev. Cell* **43**, 704–715.e5 (2017).
8. Weidinger, G. *et al.* dead end, a Novel Vertebrate Germ Plasm Component, Is Required for Zebrafish Primordial Germ Cell Migration and Survival. *Curr. Biol.* **13**, 1429–1434 (2003).
9. Ruthig, V. A. *et al.* The RNA-Binding Protein DND1 Acts Sequentially as a Negative Regulator of Pluripotency and a Positive Regulator of Epigenetic Modifiers Required for Germ Cell Reprogramming. *bioRxiv* 402008 (2018). doi:10.1101/402008
10. Youngren, K. K. *et al.* The Ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours. *Nature* **435**, 360–364 (2005).
11. Kedde, M. *et al.* RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. *Cell* **131**, 1273–86 (2007).
12. Suzuki, A., Igarashi, K., Aisaki, K. -i., Kanno, J. & Saga, Y. NANOS2 interacts with the CCR4-NOT deadenylation complex and leads to suppression of specific RNAs. *Proc. Natl. Acad. Sci.* **107**, 3594–3599 (2010).
13. Yamaji, M. *et al.* DND1 maintains germline stem cells via recruitment of the CCR4-NOT


- complex to target mRNAs. *Nature* **543**, 568–572 (2017).
14. Afroz, T., Cienikova, Z. & Cléry, A. One, Two, Three, Four! How Multiple RRM s Read the Genome Sequence. *Methods Enzymol.* **558**, 235–278 (2015).
  15. Singh, R. & Valcárcel, J. Building specificity with nonspecific RNA-binding proteins. *Nat. Struct. Mol. Biol.* **12**, 645–653 (2005).
  16. Marchler-Bauer, A. *et al.* CDD/SPARCLE: functional classification of proteins via subfamily domain architectures. *Nucleic Acids Res.* **45**, D200–D203 (2017).
  17. Cléry, A., Blatter, M. & Allain, F. H.-T. RNA recognition motifs: boring? Not quite. *Curr. Opin. Struct. Biol.* **18**, 290–298 (2008).
  18. Gerstberger, S., Hafner, M. & Tuschl, T. A census of human RNA-binding proteins. *Nat. Rev. Genet.* **15**, 829–845 (2014).
  19. Afroz, T. *et al.* A fly trap mechanism provides sequence-specific RNA recognition by CPEB proteins. *Genes Dev.* **28**, 1498–1514 (2014).
  20. Deo, R. C., Bonanno, J. B., Sonenberg, N. & Burley, S. K. Recognition of Polyadenylate RNA by the Poly(A)-Binding Protein. *Cell* **98**, 835–845 (1999).
  21. Kanaar, R., Lee, A. L., Rudner, D. Z., Wemmer, D. E. & Rio, D. C. Interaction of the sex-lethal RNA binding domains with RNA. *EMBO J.* **14**, 4530–4539 (1995).
  22. Lukavsky, P. J. *et al.* Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. *Nat. Struct. Mol. Biol.* **20**, 1443–1449 (2013).
  23. Teplova, M., Song, J., Gaw, H. Y., Teplov, A. & Patel, D. J. Structural Insights into RNA Recognition by the Alternate-Splicing Regulator CUG-Binding Protein 1. *Structure* **18**, 1364–1377 (2010).
  24. Wang, X. & Tanaka Hall, T. M. Structural basis for recognition of AU-rich element RNA by the HuD protein. *Nat. Struct. Biol.* **8**, 141–145 (2001).
  25. Hobor, F. *et al.* A cryptic RNA-binding domain mediates Syncrip recognition and exosomal partitioning of miRNA targets. *Nat. Commun.* **9**, 831 (2018).
  26. Goudarzi, M. *et al.* Identification and Regulation of a Molecular Module for Bleb-Based Cell Motility. *Dev. Cell* **23**, 210–218 (2012).
  27. Mei, W. *et al.* Maternal Dead-End1 is required for vegetal cortical microtubule assembly during *Xenopus* axis specification. *Development* **140**, 2334–44 (2013).
  28. Slanchev, K. *et al.* Control of Dead end localization and activity--implications for the function of the protein in antagonizing miRNA function. *Mech. Dev.* **126**, 270–7 (2009).
  29. Handa, N. *et al.* Structural basis for recognition of the tra mRNA precursor by the Sex-lethal protein. *Nature* **398**, 579–585 (1999).
  30. Loughlin, F. E. *et al.* The Solution Structure of FUS Bound to RNA Reveals a Bipartite Mode of RNA Recognition with Both Sequence and Shape Specificity. *Mol. Cell* **73**, 490–504.e6 (2019).
  31. Oberstrass, F. C. *et al.* Structure of PTB bound to RNA: specific binding and implications for splicing regulation. *Science* **309**, 2054–7 (2005).
  32. Dominguez, C., Fiset, J.-F., Chabot, B. & Allain, F. H.-T. Structural basis of G-tract recognition and encaging by hnRNP F quasi-RRMs. *Nat. Struct. Mol. Biol.* **17**, 853–861 (2010).
  33. Cléry, A. *et al.* Isolated pseudo-RNA-recognition motifs of SR proteins can regulate splicing using a noncanonical mode of RNA recognition. *Proc. Natl. Acad. Sci.* (2013). doi:10.1073/pnas.1303445110
  34. Dang, W. *et al.* Solution structure of the RRM domain of unnamed protein product. *PDB ID: 2DIS* (2006). doi:10.2210/PDB2DIS/PDB
  35. Moursy, A., Allain, F. H.-T. & Cléry, A. Characterization of the RNA recognition mode of hnRNP G extends its role in SMN2 splicing regulation. *Nucleic Acids Res.* **42**, 6659–72 (2014).
  36. Cieniková, Z., Damberger, F. F., Hall, J., Allain, F. H.-T. & Maris, C. Structural and Mechanistic Insights into Poly(uridine) Tract Recognition by the hnRNP C RNA Recognition Motif. *J. Am. Chem. Soc.* **136**, 14536–14544 (2014).



37. Ripin, N. *et al.* Molecular basis for AU-rich element recognition and dimerization by the HuR C-terminal RRM. *Proc. Natl. Acad. Sci.* **116**, 2935–2944 (2019).
38. Webster, M. W., Stowell, J. A. & Passmore, L. A. RNA-binding proteins distinguish between similar sequence motifs to promote targeted deadenylation by Ccr4-Not. *Elife* **8**, (2019).
39. Dominguez, D. *et al.* Sequence, Structure, and Context Preferences of Human RNA Binding Proteins. *Mol. Cell* **70**, 854–867.e9 (2018).
40. Masliah, G., Barraud, P. & Allain, F. H.-T. RNA recognition by double-stranded RNA binding domains: a matter of shape and sequence. *Cell. Mol. Life Sci.* **70**, 1875–95 (2013).
41. Beaudoin, J.-D. *et al.* Analyses of mRNA structure dynamics identify embryonic gene regulatory programs. *Nat. Struct. Mol. Biol.* **25**, 677–686 (2018).
42. Suzuki, A. *et al.* Dead end1 is an essential partner of NANOS2 for selective binding of target RNAs in male germ cell development. *EMBO Rep.* **17**, 37–46 (2016).
43. Suzuki, A., Saba, R., Miyoshi, K., Morita, Y. & Saga, Y. Interaction between NANOS2 and the CCR4-NOT Deadenylation Complex Is Essential for Male Germ Cell Development in Mouse. *PLoS One* **7**, e33558 (2012).
44. Peng, S. S., Chen, C. Y. & Shyu, A. B. Functional characterization of a non-AUUUA AU-rich element from the c-jun proto-oncogene mRNA: evidence for a novel class of AU-rich elements. *Mol. Cell. Biol.* **16**, 1490–9 (1996).
45. Wu, X. & Brewer, G. The regulation of mRNA stability in mammalian cells: 2.0. *Gene* **500**, 10–21 (2012).
46. Chen, C.-Y. *et al.* AU Binding Proteins Recruit the Exosome to Degrade ARE-Containing mRNAs. *Cell* **107**, 451–464 (2001).
47. Chou, C.-F. *et al.* Tethering KSRP, a decay-promoting AU-rich element-binding protein, to mRNAs elicits mRNA decay. *Mol. Cell. Biol.* **26**, 3695–706 (2006).
48. Lykke-Andersen, J. & Wagner, E. Recruitment and activation of mRNA decay enzymes by two ARE-mediated decay activation domains in the proteins TTP and BRF-1. *Genes Dev.* **19**, 351–61 (2005).
49. Laskowski, R., Rullmann, J. A., MacArthur, M., Kaptein, R. & Thornton, J. AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR. *J. Biomol. NMR* **8**, 477–486 (1996).
50. Studier, F. W. Protein production by auto-induction in high density shaking cultures. *Protein Expr. Purif.* **41**, 207–34 (2005).
51. Tyler, R. C. *et al.* Auto-induction medium for the production of [U-15N]- and [U-13C, U-15N]-labeled proteins for NMR screening and structure determination. *Protein Expr. Purif.* **40**, 268–278 (2005).
52. Wenter, P., Reymond, L., Auweter, S. D., Allain, F. H.-T. & Pitsch, S. Short, synthetic and selectively <sup>13</sup>C-labeled RNA sequences for the NMR structure determination of protein-RNA complexes. *Nucleic Acids Res.* **34**, e79 (2006).
53. Kibbe, W. A. OligoCalc: an online oligonucleotide properties calculator. *Nucleic Acids Res.* **35**, W43-6 (2007).
54. Vogt, M. & Taylor, V. Cross-linked RNA Immunoprecipitation. *BIO-PROTOCOL* **3**, (2013).
55. Cavanagh, J., Fairbrother, W. J., Palmer, A. G., Skelton, N. J. & Rance, M. *Protein NMR Spectroscopy* (Elsevier Inc., 2007). doi:10.1016/B978-0-12-164491-8.X5000-3
56. Delaglio, F. *et al.* NMRPipe: A multidimensional spectral processing system based on UNIX pipes. *J. Biomol. NMR* **6**, 277–293 (1995).
57. Lee, W., Tonelli, M. & Markley, J. L. NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy. *Bioinformatics* **31**, 1325–1327 (2015).
58. Salzmann, M., Pervushin, K., Wider, G., Senn, H. & Wüthrich, K. TROSY in triple-resonance experiments: New perspectives for sequential NMR assignment of large proteins. *Proc. Natl. Acad. Sci.* **95**, 13585–13590 (2002).
59. Salzmann, M., Pervushin, K., Wüthrich, K., Wider, G. & Senn, H. TROSY-type Triple-

- Resonance Experiments for Sequential NMR Assignments of Large Proteins. *J. Am. Chem. Soc.* **121**, 844–848 (2002).
60. Zhu, G., Xia, Y., Nicholson, L. K. & Sze, K. H. Protein Dynamics Measurements by TROSY-Based NMR Experiments. *J. Magn. Reson.* **143**, 423–426 (2000).
  61. Rückert, M. & Otting, G. Alignment of biological macromolecules in novel nonionic liquid crystalline media for NMR experiments. *J. Am. Chem. Soc.* **122**, 7793–7797 (2000).
  62. Herrmann, T., Güntert, P. & Wüthrich, K. Protein NMR structure determination with automated NOE-identification in the NOESY spectra using the new software ATNOS. *J. Biomol. NMR* **24**, 171–89 (2002).
  63. Herrmann, T., Güntert, P. & Wüthrich, K. Protein NMR Structure Determination with Automated NOE Assignment Using the New Software CANDID and the Torsion Angle Dynamics Algorithm DYANA. *J. Mol. Biol.* **319**, 209–227 (2002).
  64. Güntert, P. & Buchner, L. Combined automated NOE assignment and structure calculation with CYANA. *J. Biomol. NMR* **62**, 453–471 (2015).
  65. Shen, Y., Delaglio, F., Cornilescu, G. & Bax, A. TALOS+: a hybrid method for predicting protein backbone torsion angles from NMR chemical shifts. *J. Biomol. NMR* **44**, 213–223 (2009).
  66. Case, D. A. *et al.* Amber 12. *University of California, San Francisco* (2012).


## Figures and legends



**Figure 1. DND1 binds RNA targets mainly through its RRM**


**A) Domain structure of DND1 and sequence of the N-terminal part of the human protein** (Uniprot Q8IYX4) ending at the C-terminus of the tandem RRM construct used for structure determination in this work (12-235). RRM1 in grey, RRM2 in pink, N- and C-terminal conserved extensions in red, dsRBD in green. The dsRBD-truncation mutant 1-235 used in our RIP assay ends after the extension of RRM2. Red coloring in sequence indicates high conservation as described in Fig. S2. Secondary structure elements as found in our structure are indicated above the sequence. The RRM-canonical RNA binding RNP sequences are underlined below. R98 in RNP1 that was mutated for the RIP assay is indicated with one asterisk. The Ter truncation at R190 is indicated with a double asterisk and 'Ter'. See also Figs. S1 and S2. **B) RNA**

**Immunoprecipitation** from HEK293T cells transiently expressing FLAG-tagged DND1 or its mutants followed by qPCR using primers for published DND1 targets and a negative control (Table S1). Technical triplicate of a representative plot of three independent experiments is presented as relative enrichment over the input ( $2^{-\Delta Ct}$ ).  $\Delta Ct$  is an average of (Ct [RIP] – Ct [Input]) of technical triplicates with SD < 0.4. Error bars represent SD ( $\Delta Ct$ ). Results from two other independent RIP experiments are shown in Fig. S3A. DND1 and mutants are well expressed in HEK293T cell culture (Fig. S3B).




**Figure 2. Cooperative binding of DND1's tandem RRM domains to AU-rich RNA**

**A) ITC measurement of DND1's extended RRM1 domain** titrated with UUAUUU RNA.  $N = 1$  (set);  $K_D = 34.4 \pm 1.0 \mu\text{M}$ ;  $\Delta H = -4.48 \pm 0.06 \text{ kcal/mol}$ ;  $-T\Delta S = 1.6 \text{ kcal/mol}$ . **B) ITC measurement of DND1's extended tandem RRM domains** titrated with UUAUUU ( $N = 0.98 \pm 0.1$ ;  $K_D = 4.7 \pm 0.4 \mu\text{M}$ ;  $\Delta H = -33 \pm 4 \text{ kcal/mol}$ ;  $-T\Delta S = 26.1 \text{ kcal/mol}$ ) and **overlay of two 1H-15N HSQC spectra** of the free DND1 tandem RRM domains (in blue) and a 1:1 complex with UUAUUU RNA (in red) demonstrates cooperative RNA binding. NMR conditions: Protein concentration 0.2mM, 298K, 750MHz. NMR/ITC buffer: 20mM MES pH 6.6, 100 mM NaCl. See also Fig. S4 and Table S2.




**Figure 3. Solution structures of DND1's tandem RRMs bound to CUUAUUUG RNA**

**A) Ensemble of 20 superimposed lowest energy conformers.** RRM1 in grey, RRM2 in pink, conserved N- and C-terminal extensions in red. RNA in black. **B) Superimposed 20 lowest energy conformers and representative structures for eRRM1 and C) hrRRM2** within the tandem RRM-RNA complex. **D) Representative structure**, color coding as in A, RNA in yellow **E) Electrostatic surface potential plot** shows the RNA is buried in a positively charged cleft between the RRMs. See also Fig. S5 and Table S3.




**Figure 4. Intermolecular contacts between the DND1 tandem RRM1 and RRM2 domains and the CUUAUUUG RNA**  
A) schematic view of protein-RNA interactions B) U<sub>3</sub>, A<sub>4</sub> and U<sub>5</sub> base moieties C) A<sub>4</sub> and U<sub>5</sub> backbone  
D) U<sub>5</sub>, U<sub>6</sub>, and U<sub>7</sub> binding to the interdomain linker and the RRM2 binding pocket. G<sub>8</sub> binding to the eRRM1  $\beta$ -hairpin extension E) Cooperative binding by RRM1 and RRM2 to the U<sub>6</sub> and U<sub>7</sub> phosphate backbone, seen from the back of the molecule. Protein sidechains in green, RNA in yellow. Hydrogen-bonds in dots. See also Fig. S7.



**Figure 5 Introduction of an AU-rich RRE into a UTR is sufficient, RNA binding by the tandem RRM is not enough for target repression by DND1**

A wild-type TERT-UTR psiCHECK2 luciferase construct or the same construct with introduction of a single UAUUU or double UAUUUUUUUUAUUU DND1 tandem RRM target site, and either wild type or mutant FLAG-tagged DND1 were transfected into HEK293T. Relative luciferase activity is the ratio between Firefly and Renilla control luciferases, adjusted to 1 for 100%. The results are represented as means and SD from three independent experiments. 'ns':  $p > 0.05$ , \*:  $p < 0.05$ , \*\*:  $p < 0.01$ , \*\*\*:  $p < 0.001$  (two-tailed Welch's t-test). Immunostaining with anti-FLAG antibody in Fig. S3B shows that DND1 and all mutants are well expressed in HEK293T cells. See also Fig. S8.





**Figure 6. Structural comparison of tandem RRM-RNA complexes (A-D), RRMs using structural extensions to the canonical RRM fold to increase affinity to their RNA targets (D-F) and model of DND1 action mechanism**

A) The N-terminal two RRMs of HuD bound to AU-rich RNA B) The N-terminal two RRMs of PABP bound to poly(A) RNA C) The RRMs of TDP-43 bound to UG-rich RNA D) The RRMs of DND1 bound to AU-rich RNA with extensions to the canonical RRM fold shown in red E) FUS RRM bound to a stem-loop from hnRNP A2/B1 pre-mRNA F) RRM2 of PTB bound to CU-rich RNA G) model of AU-rich mRNA target repression by DND1 through recruitment of CCR4-NOT

## Main table and legend

**Table 1: NMR statistics**

Dnd1(12-235):CUUAAUUUG		
NMR Restraints		
Distance Restraints		
Protein	intramolecular	5200
	intraresidual	4947
	sequential ( i-j =1)	942
	medium range (1< i-j <5)	1313
	long range ( i-j >=5)	1190
	hydrogen bonds <sup>a</sup>	1423
RNA	intramolecular	79
	intraresidual	150
	sequential ( i-j =1)	116
	medium range (1< i-j <5)	34
	long range ( i-j >=5)	0
	hydrogen bonds	0
Complex	intermolecular	0
	long range ( i-j >=5)	103
	hydrogen bonds	103
		0
Torsion Angles <sup>b</sup>		
Protein	backbone	176
RNA	sugar pucker (DELTA)	8
RDCs		
Protein	amide NH	127
Energy Statistics <sup>c</sup>		
Average distance constraint violations		
	0.3-0.4 Å	10.3 +/- 2.5
	>0.4 Å	5.5 +/- 2.0
	Maximal (Å)	0.66 +/- 0.14
Average angle constraint violations		
	>5 degree	3.0 +/- 1.2
	Maximal (degree)	9.0 +/- 4.5
Average RDC violations		
	>5 Hz	5.2 +/- 1.2
	Maximal (Hz)	6.1 +/- 0.9
	RDC correlation coefficient	0.96 +/- 0.01
	Q = rms(Dcalc-Dobs)/rms(Dobs) (%)	30.7 +/- 2.2
	Q normalized by tensor	17.9 +/- 1.5
Mean AMBER Violation Energy		
	Constraint (kcal mol <sup>-1</sup> )	297.5 +/- 21.9
	Distance (kcal mol <sup>-1</sup> )	168.9 +/- 18.5
	Torsion (kcal mol <sup>-1</sup> )	10.7 +/- 2.4
	Alignment (kcal mol <sup>-1</sup> )	104.4 +/- 9.3
	Mean AMBER Energy (kcal mol <sup>-1</sup> )	-7568.9 +/- 18.5
Mean Deviation from ideal covalent geometry		
	Bond Length (Å)	0.0041 +/- 0.0000
	Bond Angle (degrees)	1.511 +/- 0.009
Ramachandran plot Statistics <sup>c,d</sup>		
	Residues in most favoured regions (%)	82.1 +/- 1.9
	Residues in additionally allowed regions (%)	15.3 +/- 2.1
	Residues in generously allowed regions (%)	2.0 +/- 0.8
	Residues in disallowed regions (%)	0.6 +/- 0.5
RMSD to mean structure		
Protein Dnd1 RRM1 16-133	Backbone atoms	0.95 +/- 0.23

Heavy atoms	1.23 +/- 0.20
Protein Dnd1 RRM2 134-216	
Backbone atoms	0.57 +/- 0.12
Heavy atoms	0.92 +/- 0.12
Protein Dnd1 RRM12 16-216	
Backbone atoms	1.05 +/- 0.14
Heavy atoms	1.36 +/- 0.13
RNA UAUUU	
Backbone atoms	0.43 +/- 0.13
Heavy atoms	0.60 +/- 0.18
Complex RRM12 16-216;UAUUU	
Backbone atoms	1.04 +/- 0.14
Heavy atoms	1.26 +/- 0.13

---

RMSD, root-mean-square deviation

a Hydrogen bond constraints were identified from slow exchanging amide and imino protons in D<sub>2</sub>O

b Torsion angle based on TALOS+ predictions; sugar puckers based on homonuclear TOCSY

c Dnd1 RRM12, 16-216 Chain ID: A (Sequence Range:12-235); RNA CUUAUUUG: 3-7, Chain ID: B (Sequence Range:1-8)

d Ramachandran plot, as defined by the program Procheck<sup>49</sup>.

## Methods

### REAGENTS & RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
FLAG-M2-HRP	Sigma	A8592
Bacterial and Virus Strains		
Top10 competent cells	This study	
BL21(DE3) competent cells	This study / Novagen	
Biological Samples		
DMEM	Sigma	D6429
FBS	Sigma	F7524
OptiMEM	GIBCO	31985047
Chemicals, Peptides, and Recombinant Proteins		
TEV protease	In house produced	
Critical Commercial Assays		
Clarify™ Western ECL substrate	BioRad	170-5061
Dual-Glow Luciferase Assay System	Promega	E2920
Deposited Data		
Chemical Shifts	BioMagResBank	xxx
Structural Ensemble	Protein Data Bank	xxx
Experimental Models: Cell Lines		
HEK293T cell line	ATCC	CRL-3216™
Oligonucleotides		
CUUAAUUUG RNA	Dharmacon	
selectively ribose-13C labeled RNA	This study	
Oligonucleotides for cloning & site-directed mutagenesis	Microsynth	Table S1
miRIDIAN miR-221-3p miRNA mimic	Dharmacon	MIMAT0000278
Scrambled miRNA mimic	Dharmacon	CN-001000-01-05
Recombinant DNA		
pET-M11 vector	EMBL	
pET-His-TEV	EMBL	
psiCHECK2 vector	Promega	
pCMV-SPORT6-hsDnd1 source plasmid	Source BioScience	IRATp970F0747D
pcFLAG_DNA3.1	This study / Invitrogen	
Software and Algorithms		
NMR data acquisition and processing	Topspin (Bruker)	Version 2.1
NMR data processing and relaxation analysis	NMRPipe	
Spectral analysis	NMRFAM-Sparky	Version 1.1412
Structure refinement	AMBER 12	Ff12SB force field
Structure calculation	CYANA	Version 3.98
Peak picking, structure calculation	ATNOS-CANDID	Version 3.1
Statistical analyses	PRISM	Version 6.0e

## CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Frédéric Allain ([allain@mol.biol.ethz.ch](mailto:allain@mol.biol.ethz.ch)).

## EXPERIMENTAL MODEL AND SUBJECT DETAILS

HEK293T cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, Sigma) containing 10% fetal bovine serum (FBS, Sigma) including antibiotics (0.05 mg/mL of streptomycin, and 50 U/mL of penicillin (Sigma)) in a humidified incubator (Thermo Scientific Heraeus Series 6000 Incubators, Thermo Scientific) with 5% CO<sub>2</sub> at 37°C.

## METHOD DETAILS

### Protein expression and purification

DNA fragments encoding human Dnd1 RRM1 (12-139), RRM2 (136-227) or the tandem RRM12 (12-235) were PCR amplified from the source plasmid pCMV-SPORT6-hsDnd1, an IMAGE cDNA clone (clone ID MGC:34750; IMAGE: 5172595) purchased from Source BioScience (Nottingham UK) with the primers listed in Table S1. They were cloned into the pET-M11 vector (EMBL) with an N-terminal TEV-cleavable 6xHis-tag between the NcoI and Acc65I restriction sites, using BbsI instead of NcoI to cut the insert to circumvent insert-internal restriction sites. Protein mutants were obtained by PCR-based site-directed mutagenesis with the pET-M11-RRM12 (12-235) plasmid as a template according to the QuikChange protocol (Stratagene) and the primers listed in Table S1. All protein constructs were expressed in *E. coli* BL21(DE3) cells (Novagen) in Studier-medium P-5052 supplemented with <sup>15</sup>NH<sub>4</sub>Cl or P-50501 supplemented with <sup>15</sup>NH<sub>4</sub>Cl and <sup>13</sup>C-glycerol (CIL). Precultures were grown in PA-0.5G medium<sup>50,51</sup>. Random fractionally deuterated protein for recording of triple-resonance spectra for backbone assignment was expressed in 100% D<sub>2</sub>O (CIL) in which the media components were directly dissolved. Protein was expressed for 60h at 15°C in the presence of 100 µg/mL Kanamycin. Cells were harvested by centrifugation at 4 °C, 15 min at 2,600g, and the cell pellet was resuspended in lysis buffer (20 mM Tris, pH 8, 1 M NaCl, 0.2% Triton-x-100 (w/v), 10 mM imidazole, and 2 mM 2-mercaptoethanol). Cells were lysed with two freeze-thaw cycles and three passes through the Emulsiflex cell cracker (Avestin). Before lysis 0.5mg/ml lysozyme, 25ug/ml DNaseI and 1mM Pefabloc SC (Sigma-Aldrich) was added. After centrifugation at 4 °C for 20 min at 43,000g, the cleared supernatant was sterile-filtered and loaded onto 2mL Ni-NTA beads (Qiagen), equilibrated with lysis buffer, per liter of bacterial culture. The column was washed with 10 column volumes of lysis buffer, 20 columns of lysis buffer without Triton and 5 column volumes of the same buffer with 30mM Imidazole, before the protein was eluted with elution buffer (lysis buffer without Triton and with 330 mM imidazole). For cleavage of the His<sub>6</sub> tag, the pooled fractions were dialyzed against lysis buffer (1M NaCl and no imidazole) in the presence of in-house purified TEV protease (1:100 w/w TEV:protein) at 4 °C overnight. Next day the TEV cleavage reaction was reloaded three times over a fresh Ni-NTA column to remove

the His<sub>6</sub>-TEV protease, the His<sub>6</sub>-tag fusion and contaminating proteins. The proteins were concentrated with Vivaspin 20-mL centrifugal devices with 5,000 or 10,000 MWCO (Sartorius) and buffer-exchanged into NMR buffer over PD-10 gel-filtration columns (GE-healthcare).

### RNA samples

Unlabeled RNA oligonucleotides were purchased from Dharmacon, deprotected according to the manufacturer's instructions, lyophilized and resuspended twice in water for large-scale protein-RNA complex production or NMR buffer for titrations or ITC (20mM MES pH 6.6, 100 mM NaCl). For the solid phase synthesis of selectively ribose-labeled oligos 2'-O-TOM protected ribonucleoside phosphoramidites and solid supports containing [<sup>13</sup>C<sub>5</sub>]-labeled ribose moieties were synthesized as described, followed by their sequence-specific introduction into the CUUAUUUG oligo<sup>52</sup>.

### NMR sample preparation of Protein-RNA complexes

Final protein was analyzed for nucleic acid contamination using  $A_{260nm}/A_{280nm}$  and concentration was estimated using  $A_{280nm}$  and a theoretical extinction coefficient of 18140 M<sup>-1</sup> cm<sup>-1</sup> for RRM1, 5930 M<sup>-1</sup> cm<sup>-1</sup> for RRM2 and 23470 M<sup>-1</sup> cm<sup>-1</sup> for RRM12. RNA concentrations were estimated using OligoCalc<sup>53</sup>. In the final buffer exchange step the RRM constructs were added dropwise to a 10% molar excess of RNA in the presence of 10ul of Superscript RNase inhibitor (Ambion) per sample, concentrated and further purified by size exclusion chromatography on a Sephadex 75 10/30 column (GE healthcare) in 100 mM KHPO<sub>4</sub>/ KH<sub>2</sub>PO<sub>4</sub> pH 6.6, 1 mM DTT. The fractions containing the protein-RNA complex were concentrated to 400-700 uM with Vivaspin 5-mL centrifugal devices with 10,000 MWCO (Sartorius). Before the measurements a 10% molar excess of RNA was added to saturate the protein as well as 10% v/v D<sub>2</sub>O. Complexes were lyophilized before resuspending in D<sub>2</sub>O for NMR experiments that are conducted in deuterated solvent.

### Plasmids for cell culture assays

Total RNA was extracted from cultured human fibroblasts (GM03814, Coriell Institute for Medical Research, USA). 1ug was then used for reverse transcription reaction using Oligo(dT)<sub>18</sub> and M-MuLV Reverse Transcriptase RNaseH<sup>-</sup> (Finnzymes). The 3'UTR of TERT and fragments corresponding to positions 183–282 (according to Ensembl transcript ENST00000228872) of the 3'UTR of *p27* including the predicted *miR-221* binding sites were amplified from the cDNA templates using the appropriate primers in table S1 introducing XhoI and NotI restriction sites. The Dnd1 binding site was introduced into the TERT 3'UTR insert using PCR overlap extension using the primers in table S1. 3'UTR PCR products were directionally cloned downstream of the Renilla luciferase open reading frame (ORF) of the psiCHECK2 vector (Promega) that also contains a constitutively expressed firefly luciferase gene, which was used to normalize transfections. Dnd1 fragments encoding the full-length human protein (1-353) or a dsRBD truncation (1-235) were amplified as described for the protein expression plasmids and cloned BamHI/EcoRI into an in-house modified pcDNA3.1+ plasmid (Invitrogen) with an N-terminal FLAG tag cloned NheI/HindIII. All plasmids were confirmed by sequencing and deposited at

AddGene ([www.addgene.org/Frederic\\_Allain](http://www.addgene.org/Frederic_Allain)). Plasmids for transfections were prepared using the Nucleobond Xtra midiprep kit (Macherey-Nagel) according to the manufacturer's protocol.

### **Transfections and Dual luciferase activity analysis**

HEK293T cells were transfected with Lipofectamine 2000 Reagent (Invitrogen) after seeding them 16 hours prior at  $70 \times 10^4$  cells per well (24-well plate) or  $2.8 \times 10^6$  cells per 10cm dish for immunoblotting analysis and RNA immunoprecipitation. For transfections in 24-well plates, Lipofectamine 2000 Reagent was diluted in serum free medium (OptiMEM, GIBCO) and incubated for 5 min at room temperature. Plasmid DNA (0.5  $\mu$ g per plasmid as indicated) and/or 50 nM final miR-221-3p miRNA mimic (miRIDIAN, Dharmacon) or control mimic was then added, vortexed, and incubated for 20 min at room temperature while cell culture media was exchanged to DMEM containing 10% FBS without antibiotics. Finally, the transfection complexes were added to the cell culture vessel in a drop wise manner while swirling. Transfection media were changed 6 h later to regular culture media. Luciferase activity was measured 48 hours after transfection using the Dual-Glow Luciferase Assay System (E2920 Promega, USA) on a GloMax® Discover Multimode Microplate Reader (Promega, USA). The results are represented as means and standard deviation (SD) from three independent experiments.

### **Immunoblotting analysis of protein expression and antibodies**

Total cellular protein was extracted from  $6 \times 10^5$  HEK293T cells using a RIPA buffer (1% NP-40, 150 mM NaCl, 50 mM Tris-HCl pH 8.0, 0.5% Sodium deoxycholate, 0.5% SDS) complemented with EDTA-free protease inhibitor cocktail (Roche) followed by brief sonication. Protein concentrations were determined by DC Assay (Bio-Rad). For each sample, 14  $\mu$ g of total cellular protein was separated on 12% SDS-PAGE gels and transferred on PVDF membranes. The following antibody was used: FLAG-M2-HRP (SIGMA, A8592). Immunoblots were developed using the Clarify™ Western ECL substrate (BioRad) kit and were detected using an imaging system (ChemiDoc™ MP – BioRad). All membranes were stained using a coomassie blue staining solution to ensure equal loading. The analysis was performed in triplicate.

### **RNA immunoprecipitation**

The RNA-immunoprecipitation (RIP) procedure was adapted from Vogt and Taylor<sup>54</sup>. Briefly, subconfluent cells from one 10 cm dish were harvested 48 hours after transfection, washed in PBS1X, and cross-linked with 1% formaldehyde. Glycine (0.125 M final) was added to quench the formaldehyde. Cells were pelleted by centrifugation and washed with PBS1X. Immunoprecipitation (IP) lysis buffer (50 mM HEPES at pH 7.5, 0.4 M NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM DTT, 0.5% Triton X-100, 10% glycerol) containing 1 mM PMSF, protease inhibitors (Roche), and RNase inhibitor (Thermo Scientific) was added to the cell pellet. After sonication (Bioruptor, Diagenode), cell lysates were precleared with IP Lysis buffer containing 1% BSA. 40  $\mu$ l of magnetic FLAG-M2 beads (SIGMA, M8823) were added to precleared cell lysate and incubated on a rotary wheel at 4 °C overnight. FLAG-M2 beads were washed with IP lysis buffer five times and pelleted by centrifugation. RIP buffer (50 mM HEPES at pH 7.5, 0.1 M NaCl, 5 mM EDTA, 10 mM DTT, 0.5%

Triton X-100, 10% glycerol, 1% SDS) containing RNase inhibitor was added to the pellet and incubated 1 hour at 70 °C to reverse the cross-links. After centrifugation, the supernatant was used for RNA extraction using TRIzol reagent (Life technologies) followed by a DNase I treatment and a subsequent reverse transcription with oligo d[T]<sub>18</sub> using the GoScript RT kit (Promega). One-step RT-qPCR was performed using the SYBR FAST Mix optimized for LightCycler 480 (KAPA, KK4611) with primers listed in table S1. The results are presented as relative enrichment over the input ( $2^{-\Delta Ct}$ ).  $\Delta Ct$  is an average of (Ct [RIP] – Ct [Input]) of technical triplicates with SD < 0.4. Three independent RIP experiments were performed.

### NMR data collection and assignments

All NMR spectra were recorded at 298K on Bruker AVIII600 MHz, AVIII700 MHz, and Avance 900 MHz spectrometers equipped with cryoprobes and a Bruker AVIII750MHz spectrometer using standard NMR experiments if not mentioned otherwise<sup>55</sup>. The data were processed using Topspin 3.1 (Bruker) and NMR Pipe<sup>56</sup> and analyzed with NMR-FAM-SPARKY<sup>57</sup>. Sequence-specific backbone assignments were 93% complete for non-proline residues and were obtained from 2D <sup>1</sup>H-<sup>15</sup>N HSQC, 2D <sup>1</sup>H-<sup>13</sup>C-HSQC, 3D <sup>1</sup>H-<sup>15</sup>N-NOESY ( $t_{mix} = 120$  ms) and a suite of 3D TROSY-based backbone experiments (HNCO, HN(CA)CO, HNCA, HN(CO)CA, HNCACB and HN(CO)CACB)<sup>58,59</sup> run on a random fractionally deuterated <sup>13</sup>C,<sup>15</sup>N-labeled (1:1.1) tandem RRM-CUUAUUUG complex. Sidechain protons were assigned to 80% completeness using 3D <sup>1</sup>H-<sup>15</sup>N-NOESY ( $t_{mix} = 120$  ms), 3D <sup>1</sup>H-<sup>13</sup>C-HMQC-NOESY ( $t_{mix} = 70$  ms), 3D <sup>1</sup>H-<sup>13</sup>C-HSQC-aromatic-NOESY ( $t_{mix} = 80$  ms), 3D (H)CCH- ( $t_{mix} = 21.7$  ms) and HC(C)H-TOCSY ( $t_{mix} = 23$  ms) and 3D H(C)CH-COSY on a sample of fully protonated <sup>13</sup>C,<sup>15</sup>N-labeled (1:1.1) tandem RRM-CUUAUUUG complex. Sidechains in the free <sup>13</sup>C,<sup>15</sup>N-labeled RRM2 were assigned using H(C)(CCCO)NH-TOCSY ( $t_{mix} = 17.75$  ms) and (H)C(CCCO)NH-TOCSY ( $t_{mix} = 17.75$  ms) and transferred to the RRM12-CUUAUUUG complex where this was possible. RNA was assigned using the following set of spectra: 2D TOCSY ( $t_{mix} = 60$  ms), 2D NOESY ( $t_{mix} = 150$  ms) recorded on a 1:1 complex of unlabeled tandem RRM-CUUAUUUG complex. 2D <sup>1</sup>H-<sup>13</sup>C-HSQC recorded on 1:1 complexes between unlabeled tandem RRMs and selectively <sup>13</sup>C ribose-labeled C\*UU\*AU\*UU\*G or CU\*UA\*UU\*UG\* RNA where an asterix after the nucleotide represents a <sup>13</sup>C labeled ribose moiety. 2D F<sub>2</sub> filtered NOESY ( $t_{mix} = 120$  ms) and 2D F<sub>1</sub> filtered, F<sub>2</sub> filtered NOESY recorded on <sup>13</sup>C,<sup>15</sup>N-labeled tandem RRMs in 1:1 complex with 1) unlabeled CUUAUUUG RNA 2) selectively <sup>13</sup>C ribose-labeled C\*UU\*AU\*UU\*G RNA 3) selectively <sup>13</sup>C ribose-labeled CU\*UA\*UU\*UG\* RNA. Sugar puckers in the complex were identified from 2D <sup>1</sup>H-<sup>1</sup>H- TOCSY ( $t_{mix} = 60$  ms). Strong H1'-H2' and weak H3'-H4' cross-peaks defined all puckers as C2'-endo. All  $\chi$  dihedral angles were restrained to anti conformations based on lack of strong intraresidue H1'-H6/H8 NOEs. Intermolecular NOEs were identified using 2D <sup>13</sup>C F<sub>2</sub> filtered 2D NOESY ( $t_{mix} = 60$ ms) and 3D F<sub>3</sub> filtered, F<sub>2</sub> edited <sup>13</sup>C HMQC-NOESY ( $t_{mix} = 70$  ms) in D<sub>2</sub>O. Intramolecular NOEs of RNA were identified using 2D <sup>13</sup>C F<sub>1</sub> filtered, F<sub>2</sub> filtered NOESY ( $t_{mix} = 150$ ms) in D<sub>2</sub>O.



## NMR titrations

NMR titrations were performed by adding unlabeled concentrated RNA (1-5mM) to <sup>15</sup>N-labeled protein (0.1-0.2mM) in NMR buffer (20mM MES pH 6.6, 100 mM NaCl) and monitored by <sup>1</sup>H-<sup>15</sup>N-HSQC. To monitor the chemical shift perturbations of the tandem RRM mutants upon addition of RNA, 1:1 complexes were directly prepared in NMR buffer (100 mM KHPO<sub>4</sub>/ KH<sub>2</sub>PO<sub>4</sub> pH 6.6, 1 mM DTT) as described under 'NMR sample preparation'.

## NMR relaxation and RDC measurements

Backbone dynamics data of the tandem RRMs in complex with CUUAUUUG were recorded on a 1:1.1 complex of random fractionally deuterated <sup>13</sup>C,<sup>15</sup>N-labeled protein with unlabeled RNA on a Bruker AVANCE 750 MHz spectrometer at 298 K. The heteronuclear <sup>1</sup>H-<sup>15</sup>N values were measured with reference and NOE experiments recorded in interleaved fashion, employing water flip-back pulses. Heteronuclear NOE values are reported as the ratio of peak heights in paired spectra collected with and without an initial period (4 s) of proton saturation during the 5-s recycle delay. <sup>15</sup>N T1 and T2 values were measured using TROSY-based pseudo-3D experiments employing flip-back pulses and gradient selection<sup>60</sup>. T1 spectra were acquired with delays, T = 40, 150, 300, 500, 900, 1500, 2200 and 3000 ms, T2 spectra were acquired with CPMG delays, T = 17, 34, 51, 68, 103, 137, 188, and 239 ms. <sup>15</sup>N T1 and T2 values were extracted by plotting the decay of HN volumes and fitting the curves with standard exponential equations using the nlinLS lineshape fitting program within the NMRPipe package<sup>56</sup>. Residual dipolar coupling (RDC) restraints were extracted using <sup>1</sup>H-<sup>15</sup>N TROSY run on a fully protonated <sup>15</sup>N-labeled (1:1.1) tandem RRM-CUUAUUUG complex in NMR buffer (isotropic dataset) and NMR buffer mixed with 4.2% C12E5 polyethylene glycol / hexanol medium<sup>61</sup> (anisotropic dataset). RDCs were derived by subtracting the isotropic from anisotropic <sup>1</sup>H chemical shift differences between TROSY and anti-TROSY spectra recorded in an interleaved manner. Only un-overlapped peaks were analyzed and RDC restraints were employed only for structured residues with <sup>15</sup>N het-NOE values larger than 0.6. The RDC rhombicity and anisotropy components were determined in CYANA by grid-search using an initial protein structure and further refined in subsequent structure calculations.

## Structure calculation and refinement

Intramolecular protein distance restraints were derived from 3D <sup>1</sup>H-<sup>15</sup>N NOESY ( $t_{\text{mix}} = 80\text{ms}$ ) and 3D <sup>1</sup>H-<sup>13</sup>C HMQC-NOESY ( $t_{\text{mix}} = 70\text{ms}$ ), 3D <sup>1</sup>H-<sup>13</sup>C HSQC-aroNOESY ( $t_{\text{mix}} = 80\text{ms}$ ) and 2D NOESY ( $t_{\text{mix}} = 80\text{ms}$ ). The protein resonance assignments of the tandem RRM-CUUAUUUG complex and a list of manually assigned protein core NOEs were used as input for automatic peak picking and NOESY assignment using ATNOSCANDID<sup>62,63</sup> in a two-step procedure. First intra-RRM NOEs were assigned by including only resonance assignments for one individual RRM in two separate runs. Second an ATNOSCANDID NOE assignment was performed using all resonance assignments. In this run a list of upper limit distance restraints combining the restraints obtained in the runs performed with assignments for the individual RRMs was included. This procedure was found to be necessary to obtain the correct global topology for the two RRMs. The resulting peak lists were then checked and

supplemented manually with additional picked peaks and several critical manual NOE assignments. The optimized NOESY peak lists from this procedure were re-assigned with the NOEASSIGN module of CYANA 3.96<sup>64</sup> while iteratively adjusting and keeping key manual assignments fixed during iterative refinement of the structure. Intra-protein hydrogen bonds were identified for HN resonances which were protected during hydrogen-deuterium exchange by reference to intermediate structures and added as restraints in further rounds of structure calculation. Following the determination of the protein structure in the bound state the structure of the complex was determined. Intra-RNA and intermolecular NOESY peaks were picked and assigned manually and calibrated using known distances of H5-H6 cross-peaks of pyrimidines. In structure calculations including the RNA, unambiguous intermolecular NOEs were included first for initial positioning of the nucleotides. Intermolecular NOEs with ambiguous assignments were then included as ambiguous restraints in CYANA and assigned unambiguously based on preliminary calculations. To further confirm the intermolecular restraints, we back-calculated short intermolecular distances from our final structures and inspected the spectra for completeness of intermolecular NOEs. Final structure calculations in CYANA included intra-protein, intra-RNA and intermolecular NOEs, protein dihedral backbone restraints, intra protein hydrogen bond restraints, and restraints for sugar pucker and syn or anti conformations identified from NOE patterns of H6 or H8 resonances. Protein dihedral backbone restraints derived from TALOS+<sup>65</sup> and additional manually defined  $\beta$ -hairpin turn restraints were used for the N-terminal  $\beta$ -hairpin extension. In the final structure calculation 500 structures were calculated with CYANA and the 50 lowest energy structures were selected for refinement with the SANDER module of AMBER12<sup>66</sup> using the ff12SB force field with implicit solvent and 20 were selected based on the criteria of lowest amber energy and lowest intermolecular restraint violations.

### **Isothermal Titration Calorimetry**

ITC experiments were performed on a VP-ITC microcalorimeter (Microcal). Protein was dialyzed in ITC buffer 20mM MES pH 6.6, 100 mM NaCl, 1mM 2-mercaptoethanol. RNA (100-400  $\mu$ M) was dissolved in ITC buffer and titrated into protein (3.5-11  $\mu$ M) in 2  $\mu$ L followed by 8  $\mu$ L (RRM12) or 10  $\mu$ L (RRM1) every 300 s at 25 °C with a stirring rate of 307 rpm. Raw data was analyzed in Origin 7.0.

### **Data deposition**

The coordinates for the structural models of DND1-RRM12:CUUAUUUG have been deposited in the Protein Data Bank under ID code PDB xxx, and the assignments have been deposited at BMRB under ID code BMRB: xxx.